Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors
A risk score that includes the platelet-to-lymphocyte ratio and lactate dehydrogenase may serve as a useful model for predicting prognosis following the initiation of immune checkpoint inhibitors in patients with metastatic or unresectable urothelial carcinoma.
Authors
- Koji Shiraishi (ORCID: https://orcid.org/0000-0002-3278-7747)
- Seiji Yano (ORCID: https://orcid.org/0000-0002-6151-2988)
- Masahiro Tsuchida
- Seiji Kitahara
- Jumpei Akao
- Hiroaki Matsumoto (ORCID: https://orcid.org/0000-0003-0568-1258)
- Hirotaka Komatsu
- Kazuhiro Nagao (ORCID: https://orcid.org/0000-0001-8848-5804)
- Keita Kobayashi (ORCID: https://orcid.org/0000-0001-9279-3156)
- Chietaka Ohmi
- Yoshiaki Yamamoto (ORCID: https://orcid.org/0000-0002-8452-448X)
- Yasuhide Tei
- Kazuo Oba
- Taku Misumi
- Mitsutaka Yamamoto
- Satoru Yoshihiro
- Shigeru Sakano
Institutions
- Tokuyama (Japan) (JP)
- Yamaguchi University (JP)
- Tsuda University (JP)
- Ogori Daiichi General Hospital (JP)
- Red Cross Hospital (GR)
- Saiseikai Shimonoseki General Hospital (JP)
- Shimonoseki City Hospital (JP)
- Naga Municipal Hospital (JP)
- Yamaguchi University Hospital (JP)
- Hikari Giken (Japan) (JP)
- Shuto General Hospital (JP)
- Yamaguchi Prefecture Central Hospital (JP)
- Kokura Memorial Hospital (JP)
- Sanyo-Onoda City University (JP)
- Ube (Japan) (JP)
- Graduate School USA (US)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1093/jjco/hyae137
- Citations
- 4
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.29